Insulet Corporation has been attracting significant investor attention recently, with banks, wealth management firms, and asset management companies increasing their shareholdings. Swedish giant Swedbank AB, Czech National Bank, and multiple US firms including Aaron Wealth Advisors, Gradient Investments, and Strs Ohio have all added Insulet shares to their portfolios. This interest is perhaps due to the strong growth in the company's main product line, the Omnipod insulin delivery system. Insulet's success recently prompted a price target revaluation to $365 by Truist, while both Piper Sandler and Truist Securities reiterated a Buy rating for the company. Notably, Insulet announced the hiring of industry veteran Flavia Pease as its new CFO, a change seen as a potential trigger for stronger growth. Moreover, the company introduced an expansion of its Omnipod 5 insulin system to additional European countries and launched a striking new Omnipod colour, Mango, in partnership with Pantone. Despite occasional internal and market-related setbacks reflected in share prices, analysts maintain a positive outlook on Insulet as the company's revenues continue to grow.
Insulet Corporation PODD News Analytics from Fri, 21 Mar 2025 07:00:00 GMT to Sun, 21 Sep 2025 01:42:24 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 3
